Constitutive and IFNγ-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region

Molecular Immunology

Volumn 44, Issue 8, 2007, Pages 2036-2046

  van der Stoep, Nienke ^a   Quinten, Edwin ^a   Alblas, Gabrielle ^a   Plancke, Aurelie ^a   van Eggermond, Marja C J A ^a   Holling, Tjadine M ^a   van den Elsen, Peter J ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chromatin; Gene regulation; Melanoma; MHC; Transcription factors

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR; ANTIVIRUS AGENT; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CHROMATIN; CONTROLLED STUDY; DNA DETERMINATION; GENE ACTIVATION; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; BIOSYNTHESIS; DNA RESPONSIVE ELEMENT; DRUG EFFECT; GENE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM;

ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS II; HELA CELLS; HUMANS; INTERFERON TYPE II; JURKAT CELLS; MELANOMA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; RESPONSE ELEMENTS; TRANS-ACTIVATORS;

EID: 37849189202     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.09.013     Document Type: Article

References (32)

1. Akiyama, Y., TFSEARCH: Searching transcription factor binding sites. http://www.rwcp.or.jp/papia/.
2. Barnhill R.L. Pathology and prognostic factors. Curr. Opin. Oncol. 5 (1993) 364-376
3. Brogelli L., Moretti S., Borgognoni L., and Giannotti B. HLA-DR and 96-K antigens and intratumoral lymphocytic infiltrate in primary cutaneous melanoma as markers of tumor progression. Dermatologica 180 (1990) 69-72
4. Chang C.H., Fontes J.D., Peterlin M., and Flavell R.A. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J. Exp. Med. 180 (1994) 1367-1374
5. Chen C., and Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7 (1987) 2745-2752
6. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat. Rev. Cancer 3 (2003) 559-570
7. Collins T., Korman A.J., Wake C.T., Boss J.M., Kappes D.J., Fiers W., Ault K.A., Gimbrone Jr. M.A., Strominger J.L., and Pober J.S. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 4917-4921
8. Deffrennes V., Vedrenne J., Stolzenberg M.C., Piskurich J., Barbieri G., Ting J.P., Charron D., and Alcaide-Loridan C. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J. Immunol. 167 (2001) 98-106
9. Elder D.E., Rodeck U., Thurin J., Cardillo F., Clark W.H., Stewart R., and Herlyn M. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res. 49 (1989) 5091-5096
10. Goodwin B.L., Xi H., Tejiram R., Eason D.D., Ghosh N., Wright K.L., Nagarajan U., Boss J.M., and Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ. 12 (2001) 327-335
11. Guery J.C., Ria F., and Adorini L. Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant. J. Exp. Med. 183 (1996) 751-757
12. Heinemeyer T., Wingender E., Reuter I., Hermjakob H., Kel A.E., Kel O.V., Ignatieva E.V., Ananko E.A., Podkolodnaya O.A., Kolpakov F.A., Podkolodny N.L., and Kolchanov N.A. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucl. Acids Res. 26 (1998) 362-367
13. Holling T.M., Schooten E., Langerak A.W., and van den Elsen P.J. Regulation of MHC class II expression in human T cell malignancies. Blood 103 (2004) 1438-1444
14. Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., and Old L.J. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 156 (1982) 1755-1766
15. Kurnick J.T., Ramirez-Montagut T., Boyle L.A., Andrews D.M., Pandolfi F., Durda P.J., Butera D., Dunn I.S., Benson E.M., Gobin S.J.P., and van den Elsen P.J. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J. Immunol. 167 (2001) 1204-1211
16. Levin D., Constant S., Pasqualini T., Flavell R., and Bottomly K. Role of dendritic cells in the priming of CD4 + T lymphocytes to peptide antigen in vivo. J. Immunol. 151 (1993) 6742-6750
17. Muhlethaler-Mottet A., Otten L.A., Steimle V., and Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16 (1997) 2851-2860
18. Nagarajan U.M., Lochamy J., Chen X., Beresford G.W., Nilsen R., Jensen P.E., and Boss J.M. Class II transactivator is required for maximal expression of HLA-DOB in B cells. J. Immunol. 168 (2002) 1780-1786
19. Ostmeier H., Fuchs B., Otto F., Mawick R., Lippold A., Krieg V., and Suter L. Prognostic immunohistochemical markers of primary human melanomas. Br. J. Dermatol. 145 (2001) 203-209
20. Piskurich J.F., Linhoff M.W., Wang Y., and Ting J.P.-Y. Two distinct γ interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor β. Mol. Cell. Biol. 19 (1999) 431-440
21. Ramirez-Montagut T., Andrews D.M., Ihara A., Pervaiz S., Pandolfi F., van den Elsen P.J., Waitkus R., Boyle L.A., Hishii M., and Kurnick J.T. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of Melan-A/MART-1. Clin. Exp. Immunol. 119 (2000) 11-18
22. Rohn W.M., Lee Y.-J., and Benveniste E.N. Regulation of class II MHC expression. Crit. Rev. Immunol. 16 (1996) 311-330
23. Ruiter D.J., and Brocker E.B. Immunohistochemistry in the evaluation of melanocytic tumors. Semin. Diagn. Pathol. 10 (1993) 76-91
24. Steimle V., Otten L.A., Zufferey M., and Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75 (1993) 135-146
25. Taxman D.J., Cressman D.E., and Ting J.P.-Y. Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer. J. Immunol. 165 (2000) 1410-1416
26. Ting J.P.-Y., and Baldwin A.S. Regulation of MHC expression. Curr. Opin. Immunol. 5 (1993) 8-16
27. van den Elsen P.J., Holling T.M., Kuipers H.F., and van der Stoep N. Transcriptional regulation of antigen presentation. Curr. Opin. Immunol. 16 (2004) 67-75
28. van der Stoep N., Biesta P., Quinten E., and van den Elsen P.J. Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int. J. Cancer. 97 (2002) 501-507
29. van der Stoep N., Quinten E., and van den Elsen P.J. Transcriptional regulation of the MHCII transactivator (CIITA) promoter III: identification of a novel B cell-specific enhancer region in the 5′-UTR and an important role for CREB-1 and ATF-1 in CIITA-PIII transcriptional activation. J. Immunol. 169 (2002) 5061-5071
30. van der Stoep N., Quinten E., Marcondes Rezende M., and van den Elsen P.J. E47, IRF-4 and PU.1 synergize to induce B cell-specific activation of the class II transactivator promoter III (CIITA-PIII). Blood 104 (2004) 2849-2857
31. Versteeg R., Noordermeer I.A., Kruse-Wolters M., Ruiter D.J., and Schrier P.I. c-myc down-regulates class I HLA expression in human melanomas. EMBO J. 7 (1988) 1023-1029
32. Wilson B.S., Indiveri F., Pellegrino M.A., and Ferrone S. DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization. J. Exp. Med. 149 (1979) 658-668